Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
INSY's Cash to Debt is ranked higher than
96% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. INSY: No Debt )
INSY' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.80
INSY's Equity to Asset is ranked higher than
82% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INSY: 0.80 )
INSY' s 10-Year Equity to Asset Range
Min: -3.45   Max: 0.98
Current: 0.8

-3.45
0.98
Interest Coverage 35.09
INSY's Interest Coverage is ranked higher than
56% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: 35.09 )
INSY' s 10-Year Interest Coverage Range
Min: 35.09   Max: 9999.99
Current: 35.09

35.09
9999.99
F-Score: 5
Z-Score: 25.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 32.79
INSY's Operating margin (%) is ranked higher than
96% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. INSY: 32.79 )
INSY' s 10-Year Operating margin (%) Range
Min: -324863.64   Max: 56.36
Current: 32.79

-324863.64
56.36
Net-margin (%) 40.67
INSY's Net-margin (%) is ranked higher than
97% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. INSY: 40.67 )
INSY' s 10-Year Net-margin (%) Range
Min: -301890.91   Max: 40.67
Current: 40.67

-301890.91
40.67
ROE (%) 50.80
INSY's ROE (%) is ranked higher than
98% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. INSY: 50.80 )
INSY' s 10-Year ROE (%) Range
Min: -176.46   Max: 50.8
Current: 50.8

-176.46
50.8
ROA (%) 40.15
INSY's ROA (%) is ranked higher than
99% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. INSY: 40.15 )
INSY' s 10-Year ROA (%) Range
Min: -1100   Max: 40.15
Current: 40.15

-1100
40.15
ROC (Joel Greenblatt) (%) 126.13
INSY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. INSY: 126.13 )
INSY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3653.16   Max: 6200
Current: 126.13

-3653.16
6200
Revenue Growth (%) 457.20
INSY's Revenue Growth (%) is ranked higher than
100% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. INSY: 457.20 )
INSY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 457.2
Current: 457.2

0
457.2
» INSY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

INSY Guru Trades in Q2 2013

Chuck Royce 250,000 sh (New)
» More
Q3 2013

INSY Guru Trades in Q3 2013

Steven Cohen 7,997 sh (New)
Jim Simons 157,700 sh (New)
Chuck Royce 46,080 sh (-81.57%)
» More
Q4 2013

INSY Guru Trades in Q4 2013

Joel Greenblatt 16,108 sh (New)
Jim Simons Sold Out
Steven Cohen Sold Out
Chuck Royce Sold Out
» More
Q1 2014

INSY Guru Trades in Q1 2014

Steven Cohen 9,088 sh (New)
Jim Simons 137,080 sh (New)
Joel Greenblatt 16,982 sh (-29.72%)
» More
» Details

Insider Trades

Latest Guru Trades with INSY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-03-31 Reduce -29.72%$25.807 - $55.58 $ 29.94-24%16982
Joel Greenblatt 2013-12-31 New Buy0.02%$24.01 - $32.72 $ 29.948%16108
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.40
INSY's P/E(ttm) is ranked higher than
95% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 22.40 )
INSY' s 10-Year P/E(ttm) Range
Min: 17.73   Max: 1731.35
Current: 22.4

17.73
1731.35
P/B 10.30
INSY's P/B is ranked higher than
61% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. INSY: 10.30 )
INSY' s 10-Year P/B Range
Min: 0.03   Max: 17.41
Current: 10.3

0.03
17.41
P/S 7.85
INSY's P/S is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. INSY: 7.85 )
INSY' s 10-Year P/S Range
Min: 1.74   Max: 45119.95
Current: 7.85

1.74
45119.95
PFCF 49.10
INSY's PFCF is ranked higher than
92% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 49.10 )
INSY' s 10-Year PFCF Range
Min: 39.1   Max: 173.14
Current: 49.1

39.1
173.14
EV-to-EBIT 21.10
INSY's EV-to-EBIT is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 21.10 )
INSY' s 10-Year EV-to-EBIT Range
Min: 18.8   Max: 103.5
Current: 21.1

18.8
103.5
Current Ratio 3.66
INSY's Current Ratio is ranked higher than
71% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. INSY: 3.66 )
INSY' s 10-Year Current Ratio Range
Min: 0.14   Max: 318.82
Current: 3.66

0.14
318.82
Quick Ratio 2.88
INSY's Quick Ratio is ranked higher than
69% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. INSY: 2.88 )
INSY' s 10-Year Quick Ratio Range
Min: 0.06   Max: 318.82
Current: 2.88

0.06
318.82

Valuation & Return

vs
industry
vs
history
Price/Net Cash 45.40
INSY's Price/Net Cash is ranked higher than
74% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. INSY: 45.40 )
INSY' s 10-Year Price/Net Cash Range
Min: 0.67   Max: 72.07
Current: 45.4

0.67
72.07
Price/Net Current Asset Value 21.70
INSY's Price/Net Current Asset Value is ranked higher than
75% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. INSY: 21.70 )
INSY' s 10-Year Price/Net Current Asset Value Range
Min: 0.67   Max: 72.07
Current: 21.7

0.67
72.07
Price/Tangible Book 10.30
INSY's Price/Tangible Book is ranked higher than
68% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. INSY: 10.30 )
INSY' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 105.92
Current: 10.3

0.42
105.92
Price/Graham Number 3.10
INSY's Price/Graham Number is ranked higher than
92% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: 3.10 )
INSY' s 10-Year Price/Graham Number Range
Min: 2.12   Max: 5.97
Current: 3.1

2.12
5.97
Earnings Yield (Greenblatt) 4.60
INSY's Earnings Yield (Greenblatt) is ranked higher than
67% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. INSY: 4.60 )
INSY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 5.3
Current: 4.6

1
5.3
Forward Rate of Return (Yacktman) -111.01
INSY's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. INSY: -111.01 )
INSY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -216.7   Max: -75.6
Current: -111.01

-216.7
-75.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NPR1.Germany
Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, or BTCP, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting, or CINV, and appetite stimulation in AIDS patients. The Company's proprietary Fentanyl SL Spray and its generic Dronabinol SG Capsule product candidates are both under review for marketing approval by the U.S. Food and Drug Administration, or FDA.
» More Articles for INSY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 29 2014
MONDAY DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against INSYS... Jul 11 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against INSYS... Jul 11 2014
INSYS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and... Jul 10 2014
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against INSYS... Jul 10 2014
Insys Completes Study on Dronabinol Oral Solution Jul 09 2014
Faruqi & Faruqi, LLP Reminds Investors in INSYS Therapeutics, Inc. (INSY) of Imminent Deadline to... Jul 09 2014
INSYS Therapeutics Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor... Jul 08 2014
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a... Jul 08 2014
Insys Therapeutics Updates Timing of NDA for Dronabinol Oral Solution Jul 08 2014
EQUITY ALERT: Rosen Law Firm Reminds INSYS Therapeutics Investors of Important July 2014 Class... Jul 07 2014
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against INSYS... Jul 07 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In... Jul 04 2014
Insys Therapeutics' Epilepsy Therapy Gains FDA Orphan Drug Status Jul 03 2014
UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against INSYS... Jul 02 2014
Insys Therapeutics Reaffirms Second Quarter 2014 Revenue Guidance Jul 02 2014
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a... Jul 02 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in INSYS... Jul 01 2014
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholder Of INSYS Therapeutics, Inc. Of Upcoming... Jun 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide